Reading a Microcurrent Study: How to Tell Marketing Stats from Real Clinical Data
About the Authors
Bertica M. Rubio, M.D.
Medical Director, Antiaging Regenerative Medicine Clinic | Board-Certified Physician | Dartmouth Medical School
Dr. Bertica M. Rubio is a board-certified physician and Medical Director of the Antiaging Regenerative Medicine Clinic in Redlands, California. She earned her Bachelor of Science degree from Loyola Marymount University and her Doctor of Medicine from Dartmouth Medical School (Geisel School of Medicine). She completed her pediatrics residency at UC Irvine Medical Center.
With decades of clinical experience, Dr. Rubio specializes in age management medicine, regenerative medicine, wound healing, and growth factor therapies. Her practice integrates evidence-based medical science with advanced aesthetic and regenerative treatments, helping patients achieve optimal health and youthful vitality.
Dr. Rubio is passionate about educating patients on the science behind skincare, facial rejuvenation, and non-invasive technologies like EMS (Electrical Muscle Stimulation) for facial toning. Her articles for PureLift LAB combine rigorous medical knowledge with practical guidance for achieving real, lasting results.
Andrew Conrad Barile, PT, DPT
Doctorate of Physical Therapy (DPT), Licensed Physical Therapist (PT)
Dr. Andrew Conrad Barile is a Doctor of Physical Therapy and the CEO and Founder of Xtreem Pulse LLC. He earned his Doctorate in Physical Therapy from Daemen College and brings over two decades of clinical and entrepreneurial experience in pediatric physical therapy, craniosacral therapy, and medical device innovation. His deep understanding of human anatomy, muscle physiology, and therapeutic technology provides invaluable science-backed approach to facial rejuvenation and anti-aging solutions.
Daniel Grinberg, MD, FACS
Board-Certified Otolaryngologist & Head and Neck Surgeon | Fellow, American College of Surgeons | Assistant Clinical Professor, Mount Sinai School of Medicine
Daniel Grinberg, MD, FACS is a Board-Certified Otolaryngologist and Head & Neck Surgeon at ENT and Allergy Associates in West Nyack, NY. He earned his medical degree from Columbia University College of Physicians and Surgeons, completed his Otolaryngology residency at New York University Medical Center, and serves as Assistant Clinical Professor at Mount Sinai School of Medicine. He is a Fellow of both the American College of Surgeons and the American Academy of Otolaryngology.
Dr. Grinberg's head-and-neck surgical perspective brings PureLift LAB readers a wider clinical lens — connecting at-home EMS practice to the underlying medical anatomy with the same scientific rigor we apply to every device specification.
Prof. Dr. med. Ivo Buschmann
Chair of Angiology, Medizinische Hochschule Brandenburg | Clinic Director, University Clinic for Angiology, Brandenburg University Hospital | Former Senior Consultant, Charité Universitätsmedizin Berlin
Prof. Dr. med. Ivo Buschmann is Chair of Angiology at the Medizinische Hochschule Brandenburg Theodor Fontane (MHB) and Clinic Director of the University Clinic for Angiology at the Brandenburg University Hospital. He completed his medical training at the University of Hamburg, served as a Max-Planck Society Fellow at the Max-Planck-Institute for Heart and Lung Research, and held senior consultant positions at the Charité Universitätsmedizin Berlin Campus Virchow before being appointed Chair at MHB in 2016.
Prof. Buschmann is one of Europe's leading authorities on arteriogenesis — the flow-driven growth and remodeling of blood vessels — with more than 150 peer-reviewed publications and several US and EU patents on devices that stimulate collateral blood vessel growth through controlled shear-rate therapy. His research connects mechanical and electrical stimulation to vascular adaptation, microcirculation, and tissue perfusion.
Prof. Buschmann's contributions bring PureLift LAB readers a vascular-biology perspective that complements our existing clinical, physical-therapy, and surgical-anatomy authorship — explaining how EMS stimulation engages not only facial muscles but also the microcirculation that supplies them, and why smart delivery matters at the level of blood flow as much as muscle contraction.
Share
The at-home facial device category is full of impressive-sounding numbers. Four hundred percent ATP boost. Twelve hundred microamps of advanced microcurrent. Eighteen point six percent muscle thickness increase. Each of these has appeared in marketing materials at some point, and each carries a specific meaning that the marketing context does not always make clear. The user trying to evaluate a device based on its claimed evidence ends up navigating between numbers that look comparable but are not, and between claims that look scientific but rest on different foundations.
This article walks through how to read a microcurrent or EMS study with enough rigor to separate the marketing number from the clinical reality. It is written from the perspective of someone trying to make an informed buying decision, not from the perspective of someone trying to publish in a peer-reviewed journal, so the language is intentionally accessible.
The first question to ask
The first question to ask about any claimed result is what was actually measured. A claim like "four hundred percent ATP boost" sounds impressive, but the user evaluating the claim needs to know whether the measurement happened in cells in a petri dish, in tissue from animals, in human skin biopsies, or in any kind of clinical study with actual users on actual faces. The answer matters because the relevance of each measurement to the real-world cosmetic outcome is very different.
Cellular studies, where researchers culture cells in a lab and apply electrical stimulation, can produce dramatic numbers. The cells respond, the markers change, and the results look striking. The relevance to what happens when a device touches a human face for ten minutes a day is unclear. Cellular results provide useful evidence that an effect is possible in principle, but they are several steps removed from clinical relevance.
Animal studies bring the measurement closer to whole organisms but still have substantial translation gaps. Most cosmetic device claims that cite animal research do so because human research at the same level of detail does not exist for the device.
Clinical studies on actual humans, with documented protocols, blinded assessment where possible, and reasonable sample sizes, are the most directly relevant evidence. These are also the rarest in the device category because they are expensive and time-consuming to run.
The second question, what was the comparison
A claim of improvement is meaningful only against a baseline or a control. The second question to ask is what the result was compared to. Improvement compared to no treatment is the weakest possible comparison, because the natural variability in skin appearance from day to day can produce apparent change without any device involvement. Improvement compared to a sham device (a placebo device that looks similar but does not deliver the intended signal) is more meaningful, because it controls for the act of using a device at all. Improvement compared to another active treatment is the most rigorous, because it tells you whether the device performs better than alternatives in the user's situation.
Most cosmetic device studies use the first or second comparison type. Direct head-to-head comparisons with competing devices are rare, both because they are expensive to run and because the results would carry obvious marketing implications.
When a claim says "improvement over baseline," the user reading the claim should understand that this is the weakest of the three comparison types. The result might be real, but the comparison does not address whether the improvement is bigger than what would have happened with any other input, including doing nothing while paying attention to the face.
The third question, how many people
Sample size matters more than most marketing materials acknowledge. A study with eight users showing dramatic improvement is provocative but not conclusive. A study with a hundred users showing modest improvement is much more reliable evidence that the effect is real. The variability between individuals is large enough that small studies regularly produce results that do not replicate in larger studies.
The reasonable mental shortcut is to weight study results by approximate sample size. Studies with under twenty users in each group should be treated as hypothesis-generating rather than conclusive. Studies with fifty to a hundred users in each group are getting closer to conclusive. Studies with several hundred users provide more robust evidence.
The cosmetic device literature contains very few studies in the larger-sample range. Most published evidence is in the smaller-sample range. This is not a fatal flaw of the field, but it does mean that confident claims based on small studies should be treated with appropriate caution.
The fourth question, who funded the study
Industry-funded research is not automatically bad research, but the funding source matters. A study funded by the device manufacturer is more likely to produce results favorable to the device than an independently funded study on the same question. This is well-documented across many fields of medicine and consumer products research. The bias is rarely fraudulent in any direct sense; it operates through study design choices, what gets measured, how outcomes are reported, and what gets published versus what stays in the file drawer.
The strongest evidence base for any device category is independent research, ideally from multiple research groups, published in peer-reviewed journals, with results that agree across studies. The cosmetic device category has relatively little of this kind of evidence because the funding model has historically pushed research toward sponsor-funded studies. The user reading any claim should check whether the cited research is industry-funded or independent, and weight the confidence accordingly.
The fifth question, what is the effect size in practical terms
A statistically significant result is not the same as a practically meaningful result. Studies with enough users can detect very small effects as statistically significant, which sounds impressive in marketing materials but may translate to changes the user cannot see in the mirror.
The most useful question to ask about any reported result is what the effect size actually means in the real world. An eighteen point six percent increase in muscle thickness, for example (a number that has appeared in our own references from Kavanagh and colleagues in 2012), translates to visible changes in the resting position of the affected muscles across consistent twelve-week use. That is a practically meaningful effect size, demonstrated in a study with appropriate methodology.
Numbers like four hundred percent or twelve hundred microamps, on the other hand, often turn out to be measurements of inputs or intermediate markers rather than measurements of cosmetic outcomes. They sound dramatic but may not translate to visible change.
Putting it together
A practical mental checklist for reading any device claim looks like this. What was measured. What was the comparison. How many people were studied. Who funded the study. What does the effect size mean for what you would actually see in the mirror. Five questions, each of which takes a minute to answer if the claim is well-supported and takes much longer if it is not. If the answers to any of the five are unsatisfying, the appropriate response is to weight the claim accordingly rather than rejecting it outright.
The PureLift evidence base, available on our references hub and embedded throughout this content cluster, is built on PubMed-verified studies in the modulated EMS and facial NMES literature. The two most-cited pieces are Kavanagh and colleagues in 2012, who documented an eighteen point six percent mean increase in zygomaticus major muscle thickness across twelve weeks of facial NMES, and Omatsu and colleagues in 2024, who documented improvements in cheek volume, jawline angle, submental volume, and skin elasticity across eight weeks of split-face facial NMES. Both are clinical studies in humans, with appropriate methodology and reasonable sample sizes for the cosmetic device category.
The bottom line
Marketing numbers in the at-home facial device category vary widely in their underlying rigor. Some claims rest on clinical research in actual humans with appropriate methodology. Some rest on cellular studies that may or may not translate to visible change. Some rest on intermediate measurements that sound impressive but do not address the cosmetic outcome the user actually cares about. The five-question checklist (what was measured, what was the comparison, how many people, who funded the study, what does the effect size mean) gives the user a practical way to evaluate any device claim with appropriate rigor. Used consistently, this kind of reading separates the marketing number from the clinical reality and supports more confident buying decisions.
For more on the PureLift evidence base, see our references hub. For the modulation specifics, see Modulated vs. Fixed Frequency EMS.